re: + + aod9604 clinical trial recruitment update April 7
AOD9604 Clinical Trial Recruitment Update
We are pleased to advise that as of last Friday, 225 patients have now been enrolled in the Company’s 300-patient Phase 2b clinical trial on obesity drug AOD9604, reflecting a substantial increase in the recruitment rate.
A further update will be provided on completion of enrolment.
About Metabolic
Metabolic Pharmaceuticals Limited is a biotechnology company based in Melbourne, Australia, and listed on the Australian Stock Exchange (ASX: MBP).
The Company’s mission is to develop a pipeline of new pharmaceuticals for world markets, and currently
has active programs aimed at treating obesity (AOD9604 in Phase 2b human trials), pain
(ACV1 in preclinical toxicology), type 2 diabetes, and osteoporosis.
Further details are
available at www.metabolic.com.au.
Contact Information:
Ph +61 3 9860 5700
Chris Belyea CEO [email protected]
David Kenley VP Corporate Development [email protected]
+ + data and comment + +, page-18
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)